Overview

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Status:
Not yet recruiting

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center, Japan

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Carboplatin
Lenvatinib
Paclitaxel
Pembrolizumab